Categories Other Industries

New flu vaccine brings Novavax back to life

Novavax shares skyrocketed after the company’s latest study into its flu vaccine offered promising results. The company’s vaccine for flu, NanoFlu, generated stronger results when compared to the standard vaccines that are currently available.

The Gaithersburg, Maryland-based company had a tumultuous journey throughout 2017 after it witnessed a dramatic failure of its closely watched vaccine for respiratory infection. Though the company officials were quite confident about its success, investors started losing faith in this stock over rising concerns of its sustainability. This soon led way to takeover rumors.

Picture for representation

NanoFlu has now forced investors to change their opinion about this company.

Novavax claims that NanoFlu was almost 47-64% more effective against different strains of the nastiest H3N2, when compared to the standard flu vaccines.

Rivals Sanofi and GlaxoSmithKline have already developed their own flu vaccines and have started marketing them. However, Novavax claims that NanoFlu was almost 47-64% more effective against different strains of the nastiest H3N2, when compared to the standard flu vaccines. This marks a big achievement for Novavax, because several articles from various medical journals have highlighted how the other vaccines have been less effective against the swine flu virus.

If NanoFlu hits the right targets, investors may eventually see buyout rumors fading. The company plans to kick-start its Phase 2 trial for NanoFlu vaccine during the third quarter of this year.

Most Popular

V Earnings: Key quarterly highlights from Visa’s Q1 2023 financial results

Visa Inc. (NYSE: V) reported first quarter 2023 earnings results today. Net revenues grew 12% year-over-year to $7.9 billion. GAAP net income rose 6% to $4.2 billion while EPS grew

Earnings: Highlights of Intel’s (INTC) Q4 2022 financial results

Intel Corporation (NASDAQ: INTC) Thursday reported a decline in adjusted earnings and revenues for the fourth quarter. The semiconductor giant also provided guidance for the first quarter of 2023. Fourth-quarter

McCormick (MKC) expects to drive sales growth in 2023 through pricing actions and cost savings

Shares of McCormick & Company Inc. (NYSE: MKC) were down over 5% on Thursday after the company missed expectations on its fourth quarter 2022 results and provided a lower-than-expected earnings

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top